Horizon Adaptive Platform
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 300 patients (estimated)
- Sponsors
- Multiple Myeloma Research Consortium
- Tags
- B-Cell Maturation Antigen (BCMA), CD3, Closed Label (Masked), Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1876
- NCT Identifier
- NCT06171685
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.